Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq:BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.
Related news for (BIIB)
- Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
- Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
- Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
- Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
- Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients